Literature DB >> 28484995

Management of CAD in Patients with Active Cancer: the Interventional Cardiologists' Perspective.

Dana Elena Giza1, Kostas Marmagkiolis2, Elie Mouhayar1, Jean-Bernard Durand1, Cezar Iliescu3.   

Abstract

PURPOSE OF REVIEW: Coronary artery disease in patients with active cancer presents particular challenges for clinicians, as optimum management is required in order to treat the underlying malignancy and to reduce morbidity and mortality associated with cardiovascular diseases. Special considerations must be made in respect to either primary or secondary thrombocytopenia, the presence of coagulopathies and the propensity of bleeding, vascular access complications, and increased risk of stent thrombosis. RECENT
FINDINGS: In presence of acute coronary symptoms, the cardio-oncology team has to make a complex decision between conservative medical management or early angiography (within 24 h) and revascularization. There is a lack of reliable data on the outcomes of patients with active cancer who undergo invasive procedures for the diagnostic and treatment of coronary artery disease. Cardiac catheterization recommendations in cancer patients are being currently elaborated by cardio-oncologists in order to improve the overall survival in cancer patients with coronary artery disease.

Entities:  

Keywords:  Cancer; Cardio-oncology; Cardiotoxicity; Coronary artery disease; PCI; Radiation

Mesh:

Year:  2017        PMID: 28484995     DOI: 10.1007/s11886-017-0862-x

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  63 in total

1.  5-Fluorouracil-induced Tako-Tsubo-like syndrome.

Authors:  Cécile Basselin; Thierry Fontanges; Jacques Descotes; Philippe Chevalier; Bernard Bui-Xuan; Gwennaelle Feinard; Quadiri Timour
Journal:  Pharmacotherapy       Date:  2011-02       Impact factor: 4.705

2.  [Risk of venous thromboembolism in patients with cancer treated with cisplatin: A systematic review and meta-analysis].

Authors:  M Wilhelm
Journal:  Strahlenther Onkol       Date:  2013-08       Impact factor: 3.621

Review 3.  The prethrombotic state in cancer.

Authors:  G Luzzatto; A I Schafer
Journal:  Semin Oncol       Date:  1990-04       Impact factor: 4.929

4.  The levels of evidence and their role in evidence-based medicine.

Authors:  Patricia B Burns; Rod J Rohrich; Kevin C Chung
Journal:  Plast Reconstr Surg       Date:  2011-07       Impact factor: 4.730

Review 5.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

6.  Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.

Authors:  Vishal Ranpura; Sanjaykumar Hapani; Jeff Chuang; Shenhong Wu
Journal:  Acta Oncol       Date:  2010-04       Impact factor: 4.089

7.  Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia.

Authors:  Ayalew Tefferi; Louis Letendre
Journal:  Am J Hematol       Date:  2011-05-31       Impact factor: 10.047

8.  Impact of access site selection and operator expertise on radiation exposure; a controlled prospective study.

Authors:  Ted S Lo; Karim Ratib; Aun-Yeong Chong; Gurbir Bhatia; Mark Gunning; James Nolan
Journal:  Am Heart J       Date:  2012-10       Impact factor: 4.749

9.  Long-term prognosis of the transient left ventricular dysfunction syndrome (Tako-Tsubo cardiomyopathy): focus on malignancies.

Authors:  Christof Burgdorf; Volkhard Kurowski; Hendrik Bonnemeier; Heribert Schunkert; Peter Walter Radke
Journal:  Eur J Heart Fail       Date:  2008-08-08       Impact factor: 15.534

10.  Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention.

Authors:  Matthijs A Velders; Helèn Boden; Sjoerd H Hofma; Susanne Osanto; Bas L van der Hoeven; Anton A C M Heestermans; Suzanne C Cannegieter; J Wouter Jukema; Victor A W M Umans; Martin J Schalij; Adrianus J van Boven
Journal:  Am J Cardiol       Date:  2013-09-21       Impact factor: 2.778

View more
  3 in total

1.  Percutaneous Coronary Intervention in Patients With Gynecological Cancer: Machine Learning-Augmented Propensity Score Mortality and Cost Analysis for 383,760 Patients.

Authors:  Nicole Thomason; Dominique J Monlezun; Awad Javaid; Alexandru Filipescu; Efstratios Koutroumpakis; Fisayomi Shobayo; Peter Kim; Juan Lopez-Mattei; Mehmet Cilingiroglu; Gloria Iliescu; Kostas Marmagkiolis; Pedro T Ramirez; Cezar Iliescu
Journal:  Front Cardiovasc Med       Date:  2022-02-14

2.  Study on the Correlation Factors of Tumour Prognosis after Intravascular Interventional Therapy.

Authors:  Lei Zheng; Hua Feng; Limin Yin; Jun Wang; Wei Zhou; Sunin Tang; Mingming Li
Journal:  J Healthc Eng       Date:  2021-10-27       Impact factor: 2.682

Review 3.  Management of Acute Coronary Syndrome in Cancer Patients: It's High Time We Dealt with It.

Authors:  Fabiana Lucà; Iris Parrini; Maurizio Giuseppe Abrignani; Carmelo Massimiliano Rao; Laura Piccioni; Stefania Angela Di Fusco; Roberto Ceravolo; Irma Bisceglia; Carmine Riccio; Sandro Gelsomino; Furio Colivicchi; Michele Massimo Gulizia
Journal:  J Clin Med       Date:  2022-03-24       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.